{
    "ticker": "LCTX",
    "name": "Lineage Cell Therapeutics, Inc.",
    "description": "Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of degenerative diseases. Founded in 2014 and headquartered in Carlsbad, California, Lineage is committed to advancing regenerative medicine through its proprietary technology platforms. The company's lead product candidates are derived from its unique cell manufacturing processes that aim to restore function in damaged tissues and organs. Key therapeutic areas of focus include ophthalmology, with its lead candidate, OpRegen, targeting age-related macular degeneration (AMD), and spinal cord injury. Lineage's approach harnesses the power of stem cells to create durable, transplantable cell products designed to provide long-lasting therapeutic effects. The company is dedicated to addressing unmet medical needs and improving the quality of life for patients suffering from debilitating conditions. Through strategic collaborations and rigorous clinical trials, Lineage is poised to make significant contributions to the field of regenerative medicine, transforming how diseases are treated and managed.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Carlsbad, California, USA",
    "founded": "2014",
    "website": "https://www.lineagecell.com",
    "ceo": "Brian M. Culley",
    "social_media": {
        "twitter": "https://twitter.com/LineageCell",
        "linkedin": "https://www.linkedin.com/company/lineagecelltherapeutics/"
    },
    "investor_relations": "https://investors.lineagecell.com",
    "key_executives": [
        {
            "name": "Brian M. Culley",
            "position": "CEO"
        },
        {
            "name": "Matt W. McLain",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "OpRegen",
                "VAC2"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lineage Cell Therapeutics, Inc. | Innovating Cell Therapies",
        "meta_description": "Explore Lineage Cell Therapeutics, Inc., a leader in regenerative medicine focused on developing innovative cell therapies for degenerative diseases.",
        "keywords": [
            "Lineage Cell Therapeutics",
            "Regenerative Medicine",
            "Cell Therapy",
            "OpRegen",
            "Age-related Macular Degeneration",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What does Lineage Cell Therapeutics specialize in?",
            "answer": "Lineage Cell Therapeutics specializes in developing innovative cell therapies for degenerative diseases."
        },
        {
            "question": "Who is the CEO of Lineage Cell Therapeutics?",
            "answer": "Brian M. Culley is the CEO of Lineage Cell Therapeutics, Inc."
        },
        {
            "question": "Where is Lineage Cell Therapeutics headquartered?",
            "answer": "Lineage Cell Therapeutics is headquartered in Carlsbad, California, USA."
        },
        {
            "question": "What are Lineage's main products?",
            "answer": "Lineage's main products include OpRegen and VAC2, focusing on cell therapies for various conditions."
        },
        {
            "question": "When was Lineage Cell Therapeutics founded?",
            "answer": "Lineage Cell Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "RGEN",
        "CRBP",
        "CGEN",
        "PGEN"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "GILD",
        "REGN"
    ]
}